AIMS: This prospective, randomized study was initiated to assess the impact of pharmacokinetically (PK)-guided paclitaxel (PTX) dosing on toxicity and efficacy compared with body-surface area (BSA)-based dosing in Chinese non-small cell lung cancer patients. METHODS: A total of 319 stage IIIB/IV non-small cell lung cancer patients receiving first-line chemotherapy were enrolled. Patients were randomized to receive 3-weekly carboplatin plus PTX at a starting dose of 175 mg/m2 with subsequent PTX dosing based on either BSA or PK-guided dosing targeting time above a PTX plasma concentration of 0.05 μmol/L (PTXTc > 0.05 ) between 26 and 31 hours. The primary safety endpoint was grade 4 haematological toxicity. The secondary endpoints were neuropathy, objective response rate, progression-free survival and overall survival. RESULTS: In total, 275 (86%) patients completed ≥2 cycles of chemotherapy (140 in BSA arm and 135 in PK arm). In cycle 1, with the same PTX dose, average PTXTc > 0.05 was 37 hours (range = 18-57 hours). Over cycles 2-4, patients in the PK arm had significantly lower average PTX doses and exposure compared with the BSA arm (128 vs 161 mg/m2 , P < .0001 and 29 vs 35 hours, P < .0001). PK-guided dosing significantly reduced the cumulative incidence of grade 4 haematological toxicity (15% vs 24%, P = .004), grade 4 neutropenia (15% vs 23%, P = .009) and grade ≥ 2 neuropathy (8% vs 21%, P = .005). Objective response rate (32% vs 26%, P = .28) and overall survival (21.0 vs 24.0 months, P = .815) were similar in PK and BSA arms. Progression-free survival was slightly improved in PK arm (4.67 vs 4.17 months, P = .026). CONCLUSION:PK-guided PTX dosing significantly reduced grade 4 haematological toxicities and grade ≥ 2 neuropathy without an adverse impact on clinical outcomes.
RCT Entities:
AIMS: This prospective, randomized study was initiated to assess the impact of pharmacokinetically (PK)-guided paclitaxel (PTX) dosing on toxicity and efficacy compared with body-surface area (BSA)-based dosing in Chinese non-small cell lung cancerpatients. METHODS: A total of 319 stage IIIB/IV non-small cell lung cancerpatients receiving first-line chemotherapy were enrolled. Patients were randomized to receive 3-weekly carboplatin plus PTX at a starting dose of 175 mg/m2 with subsequent PTX dosing based on either BSA or PK-guided dosing targeting time above a PTX plasma concentration of 0.05 μmol/L (PTXTc > 0.05 ) between 26 and 31 hours. The primary safety endpoint was grade 4 haematological toxicity. The secondary endpoints were neuropathy, objective response rate, progression-free survival and overall survival. RESULTS: In total, 275 (86%) patients completed ≥2 cycles of chemotherapy (140 in BSA arm and 135 in PK arm). In cycle 1, with the same PTX dose, average PTXTc > 0.05 was 37 hours (range = 18-57 hours). Over cycles 2-4, patients in the PK arm had significantly lower average PTX doses and exposure compared with the BSA arm (128 vs 161 mg/m2 , P < .0001 and 29 vs 35 hours, P < .0001). PK-guided dosing significantly reduced the cumulative incidence of grade 4 haematological toxicity (15% vs 24%, P = .004), grade 4 neutropenia (15% vs 23%, P = .009) and grade ≥ 2 neuropathy (8% vs 21%, P = .005). Objective response rate (32% vs 26%, P = .28) and overall survival (21.0 vs 24.0 months, P = .815) were similar in PK and BSA arms. Progression-free survival was slightly improved in PK arm (4.67 vs 4.17 months, P = .026). CONCLUSION: PK-guided PTX dosing significantly reduced grade 4 haematological toxicities and grade ≥ 2 neuropathy without an adverse impact on clinical outcomes.
Authors: Markus Joerger; Alwin D R Huitema; Desiree H J G van den Bongard; Jan H M Schellens; Jos H Beijnen Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: Antonius A Miller; Gary L Rosner; Merrill J Egorin; Donna Hollis; Stuart M Lichtman; Mark J Ratain Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: Sophie Callies; Dinesh P de Alwis; Adrian Harris; Paul Vasey; Jos H Beijnen; Jan H Schellens; Michael Burgess; Leon Aarons Journal: Br J Clin Pharmacol Date: 2003-07 Impact factor: 4.335
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: L Gianni; C M Kearns; A Giani; G Capri; L Viganó; A Lacatelli; G Bonadonna; M J Egorin Journal: J Clin Oncol Date: 1995-01 Impact factor: 44.544
Authors: Anne-Joy M de Graan; Laure Elens; Jason A Sprowl; Alex Sparreboom; Lena E Friberg; Bronno van der Holt; Pleun J de Raaf; Peter de Bruijn; Frederike K Engels; Ferry A L M Eskens; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen; Ron H N van Schaik Journal: Clin Cancer Res Date: 2013-05-02 Impact factor: 12.531
Authors: René J Boosman; Jacobus A Burgers; Egbert F Smit; Neeltje Steeghs; Anthonie J van der Wekken; Jos H Beijnen; Alwin D R Huitema; Rob Ter Heine Journal: Drugs Date: 2021-12-11 Impact factor: 9.546
Authors: Daniel L Hertz; Li Chen; N Lynn Henry; Jennifer J Griggs; Daniel F Hayes; Brian A Derstine; Grace L Su; Stewart C Wang; Manjunath P Pai Journal: Br J Clin Pharmacol Date: 2022-02-14 Impact factor: 3.716
Authors: Li Chen; Ciao-Sin Chen; Yihan Sun; N Lynn Henry; Kathleen A Stringer; Daniel L Hertz Journal: Cancer Chemother Pharmacol Date: 2021-06-05 Impact factor: 3.288
Authors: Zuzanna Angehrn; Liina Haldna; Anthe S Zandvliet; Eva Gil Berglund; Joost Zeeuw; Billy Amzal; S Y Amy Cheung; Thomas M Polasek; Marc Pfister; Thomas Kerbusch; Niedre M Heckman Journal: Front Pharmacol Date: 2020-06-18 Impact factor: 5.810